– Multiple SBIR/STTR Submission Deadlines Quickly Approaching –
BioHealth Innovation, Inc. (BHI), a regional private-public partnership focusing on commercializing market-relevant biohealth innovations and increasing access to early-stage funding in Central Maryland, announced today the launch of its Commercial Relevance Program (CRP). BHI’s CRP is designed to help life science companies navigate the complicated process of preparing applications for federal funding, inclusive of Small Business Innovation Research (SBIR), Small Business Technology Transfer (STTR), and other federal government awards.
“The federal grant application process can be very complex. Based on 2012 data released by the National Institutes of Health (NIH), Maryland ranks 32nd out of 50 states with regard to SBIR award success rates. We would like to improve on this – and are confident that the CRP will help companies be more successful with their submissions,” said Ethan Byler, Director, Innovation Programs, BioHealth Innovation, Inc.
“At the end of the day, it’s about helping Central Maryland companies to get the best results possible as they seek out federal grant awards as a means of non-dilutive funding,” he added.
The CRP incorporates a pre-proposal review by knowledgeable BHI staff and advisors prior to a life science company’s submission of a full proposal. Through this review process, applicants will receive a set of recommendations and tips for troubleshooting their proposal for federal funding.
Interested life science companies in Central Maryland should contact BHI today for more information. The following federal agency SBIR/STTR deadlines are fast approaching:
- NIH SBIR/STTR Deadline – April 5, 2013
http://grants.nih.gov/grants/funding/sbir.htm - NSF SBIR/STTR Deadline – June 11, 2013
http://www.nsf.gov/eng/iip/sbir/index.jsp - DOD SBIR/STTR Deadline – June 26, 2013
http://www.acq.osd.mil/osbp/sbir/sb/schedule.shtml
About BioHealth Innovation, Inc.
BioHealth Innovation, Inc., is a regional innovation intermediary focused on commercializing market-relevant bio-health innovations and increasing access to early-stage funding in Maryland. Learn more at www.biohealthinnovation.org.
Rick Soni is the President and Chief Operating Officer of Rexahn Pharmaceuticals, a publically-traded clinical stage biopharmaceutical company. He has held this position since August, 2009. Prior to that, he also served as Chief Business Officer from July 2008 to August 2009. While at Rexahn, Mr. Soni has been instrumental in transforming Rexahn from a discovery stage company to a clinical stage company and has formed a major licensing partnership between Rexahn and Teva Pharmaceuticals.
Prior to joining Rexahn, Mr. Soni held various management positions within Otsuka from June 1997 until July 2008 and was responsible for development and commercialization of otsuka’s successful product portfolio. Prior to Otsuka, Mr. Soni also held several management roles within New Product Planning, Sales and Marketing at Novartis and Schering-Plough (now Merck).
Mr. Soni received his undergraduate degree in Industrial Engineering from University of Wisconsin- Madison and an MBA from Fairleigh Dickinson University.
Biopharmaceutical giant AstraZeneca announced today it plans to create a research and development center in Gaithersburg, adding 300 jobs at MedImmune’s current location.
MedImmune’s director of corporate public relations, Tracy Rossin, said no new buildings are planned at this point. Biotech company MedImmune, which is owned by AstraZeneca, currently houses AstraZeneca’s biologics programs, geared toward the creation of vaccines and medications.
Vice President, R&D, University of Maryland, Baltimore
Jim Hughes became Vice President of Research and Development for the University of Maryland, Baltimore (UMB) in December 2001. UMB’s nationally prominent schools of dentistry, law, medicine, nursing, pharmacy, and social work make it one of the top ten public academic healthcare centers in the country. Mr. Hughes’ office is responsible for expanding and administering sponsored research and technology commercialization at UMB. He is also leading UMB’s efforts to develop the UMB Bio Park, an ten-acre, one million square-foot research park that will employ over 2500 people. Prior to joining UMB, Mr. Hughes worked for the Maryland Department of Business and Economic Development (DBED) for six years, most recently as director of Technology and International Business. He led DBED’s efforts to recruit foreign-based businesses and technology-driven businesses to locate facilities in Maryland. Mr. Hughes has an MBA from the Columbia Business School and a BA from Davidson College.
One big East Coast pharmaceutical firm abandoned work on a hepatitis C drug this week, while another shuttered a young company that had cost it $720 million to acquire. But new ideas continue to burst forth, and investors pitched in $20 million for another hopeful startup.
The Connecticut company that figured out how to make a recombinant flu vaccine is now trying to invent a marketing strategy for it. And in New Jersey, one of the biggest sources of marketing data for drug companies snapped up a startup that helps organize all that information.
…
|
Read more http://www.grants.gov/search/search.do?mode=VIEW&oppId=227088